Rare Disease Innovation at the FDA—Opportunities for Implementation
JAMA · 17.12.2024 · 332 (23) · 1973
DOI: 10.1001/jama.2024.20358 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 17.12.2024. Verfasst von Carolyn K Shore und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Academies of Sciences, Engineering, and Medicine, Washington, DC. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses new pathways for researchers to seek collaboration when conducting studies on treatments for rare diseases and conditions.
Autor:innen und Institutionen
- National Academies of Sciences, Engineering, and Medicine, Washington, DC.
- Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland.
Zitieren
APA
Shore, C. K., Worku, T. L., & Kahn, J. (2024). Rare Disease Innovation at the FDA—Opportunities for Implementation. JAMA, 332(23), 1973. https://doi.org/10.1001/jama.2024.20358
Vancouver
Shore CK, Worku TL, Kahn J. Rare Disease Innovation at the FDA—Opportunities for Implementation. JAMA. 2024;332(23):1973. doi:10.1001/jama.2024.20358
BibTeX
@article{Shore2024,
author = {Shore, Carolyn K and Worku, Tequam L and Kahn, Jeffrey},
title = {Rare Disease Innovation at the FDA—Opportunities for Implementation},
journal = {JAMA},
year = {2024},
volume = {332},
number = {23},
pages = {1973},
doi = {10.1001/jama.2024.20358}
}
EUVIMED